# Granite Point Capital

> Granite Point Capital is a VC fund backing Biotechnology and Internet. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 11
- Last investment: Jun 2022
- Lead investor: 27%
- Last updated: Aug 2026
- Website: http://www.granitepoint.com

Granite Point Capital is a hedge fund. They have closed-end investment office in Boston, MA.Jeffrey Barnett, the chief operating officer of Granite Point Capital in Boston, is responsible for all aspects of the firm's business, including human resources, systems, trading, compliance and risk management. He also serves on the firm'sinvestment committee, and has been instrumental in crafting a number of its investments in private equity transactions. Launched in February of 2004, Granite Point Capital is a research-driven, long/short equity hedge fund with a global mandate and a focus on mid-small cap US equities. Although primarily focused on the public markets, it has invested in a number of PIPEs, private equity and venture-backed companies.

## Contacts

5 contacts available for Granite Point Capital. Shizune tracks 3 team members at Granite Point Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/granite-point-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 27% |
| Internet | 2 | 18% |
| Health Care | 2 | 18% |
| Therapeutics | 2 | 18% |
| News | 1 | 9% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 27% |
| Series A | 2 | 18% |
| Series C | 2 | 18% |
| Venture - Series Unknown | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeff Barnett | Chief Operating Officer | 0 | https://shizune.co/investors/profile/jeff-barnett |
| Scott Bushley | Partner, Finances & Operations | 0 | https://shizune.co/investors/profile/scott-bushley |
| Warren Lammert | Founder & CIO | 5 | https://shizune.co/investors/profile/warren-lammert |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cerebral Therapeutics | Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $40M | Series C | Jun 28, 2022 |  |
| Cerebral Therapeutics | Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $40M | Series C | Jun 28, 2022 |  |
| Receptor Life Sciences | Receptor Life Sciences is a biotechnology company | $9.7M | Series A | Apr 07, 2022 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M | Series B | Nov 03, 2021 |  |
| Teikametrics | Teikametrics is an internet company that features an eCommerce optimization platform designed for retailers on online marketplaces. Its software platform specializes in pricing optimization, operations, and inventory for sellers of all sizes. The company was founded in 2015 and is headquartered in Boston, Massachusetts. | $40M | Series B | Jul 15, 2021 |  |
| Antios Therapeutics | Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $96M | Series B | Apr 12, 2021 |  |
| Teikametrics | Teikametrics is an internet company that features an eCommerce optimization platform designed for retailers on online marketplaces. Its software platform specializes in pricing optimization, operations, and inventory for sellers of all sizes. The company was founded in 2015 and is headquartered in Boston, Massachusetts. | $15M | Venture - Series Unknown | Feb 20, 2020 |  |
| Cerebral Therapeutics | Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $35M | Series B | Jan 06, 2020 |  |
| Cerebral Therapeutics | Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $7.8M | Series A | Mar 08, 2019 |  |
| Cerebral Therapeutics | Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $3M | Series A | Jun 20, 2018 |  |

10 of 11 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 5 deals together
- [Soleus Capital](https://shizune.co/investors/profile/soleus-capital) — VC Fund, 4 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Granite Point Capital invest in?

Granite Point Capital invests primarily in Biotechnology, Internet and Health Care startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Granite Point Capital?

Public channels for Granite Point Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Granite Point Capital?

The team at Granite Point Capital includes Jeff Barnett (Chief Operating Officer), Scott Bushley (Partner, Finances & Operations) and Warren Lammert (Founder & CIO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co